Payment overview · 2025
General Payments
$1,002.93
52 reported records · 18 companies
Healthcare provider profile · identity verified
Mark A Perez, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAS VEGAS, NV · NPI 1720152473
Verified facts
What the public records show
CMS Open Payments records show Mark A Perez, MD received $1,002.93 in general payments during 2025 across 52 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 328 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $265.41 | 26.5% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $222.07 | 22.1% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.69 | 7.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.39 | 7.2% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $56.16 | 5.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.85 | 4.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.64 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.59 | 3.1% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $28.36 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.44 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.43 | 2.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.00 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.93 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.46 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.75 | 1.8% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $17.67 | 1.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $13.72 | 1.4% | 1 | 2025 |
| Biocomposites Inc | Unresolved — no canonical attribution shown | $11.37 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,002.93 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $265.41 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $177.55 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $139.67 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.69 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.39 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $56.16 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.96 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.43 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Stimulan Normalized: stimulan |
Device | Biocomposites Inc | $11.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 87 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 256 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
256 | 57 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
66 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
328 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 626 | 195 |
| Losartan Potassium | Losartan Potassium | 552 | 164 |
| Metformin Hcl | Metformin Hcl | 550 | 174 |
| Omeprazole | Omeprazole | 534 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 141 |
| Lisinopril | Lisinopril | 495 | 145 |
| Diclofenac Sodium | Diclofenac Sodium | 490 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 126 |
| Gabapentin | Gabapentin | 418 | 128 |
| Famotidine | Famotidine | 338 | 97 |
| Mounjaro | Tirzepatide | 328 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 85 |
| Farxiga | Dapagliflozin Propanediol | 256 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 68 |
| Alendronate Sodium | Alendronate Sodium | 231 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 217 | 72 |
| Montelukast Sodium | Montelukast Sodium | 196 | 52 |
| Simvastatin | Simvastatin | 193 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 188 | 81 |
| Vascepa | Icosapent Ethyl | 188 | 40 |
| Meloxicam | Meloxicam | 187 | 72 |
| Furosemide | Furosemide | 186 | 57 |
| Trazodone Hcl | Trazodone Hcl | 185 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 51 |
| Alprazolam | Alprazolam | 173 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 56 |
| Celecoxib | Celecoxib | 171 | 72 |
| Clonidine Hcl | Clonidine Hcl | 168 | 67 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 152 | 52 |
| Januvia | Sitagliptin Phosphate | 150 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 146 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 44 |
| Potassium Chloride | Potassium Chloride | 131 | 29 |
| Jardiance | Empagliflozin | 126 | 37 |
| Finasteride | Finasteride | 113 | 37 |
| Linzess | Linaclotide | 113 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 34 |
| Azithromycin | Azithromycin | 110 | 86 |
| Carvedilol | Carvedilol | 110 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 106 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 104 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 51 |
| Ibuprofen | Ibuprofen | 103 | 45 |
| Glipizide Er | Glipizide | 99 | 35 |
| Prednisone | Prednisone | 97 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 22 |
| Donepezil Hcl | Donepezil Hcl | 88 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 71 |
| Eliquis | Apixaban | 87 | 25 |
| Methylprednisolone | Methylprednisolone | 86 | 70 |
| Lidocaine | Lidocaine | 85 | 21 |
| Allopurinol | Allopurinol | 84 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 22 |
| Methocarbamol | Methocarbamol | 80 | 40 |
| Tramadol Hcl | Tramadol Hcl | 80 | 36 |
| Atenolol | Atenolol | 79 | 26 |
| Metformin Hcl Er | Metformin Hcl | 75 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 26 |
| Megestrol Acetate | Megestrol Acetate | 71 | 28 |
| Glipizide | Glipizide | 68 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 52 |
| Sertraline Hcl | Sertraline Hcl | 66 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 66 | 24 |
| Azelastine Hcl | Azelastine Hcl | 63 | 27 |
| Levofloxacin | Levofloxacin | 61 | 53 |
| Naproxen | Naproxen | 61 | 28 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 30 |
| Pregabalin | Pregabalin | 59 | 22 |
| Xarelto | Rivaroxaban | 59 | 17 |
| Tradjenta | Linagliptin | 57 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 26 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | 28 |
| Chlorthalidone | Chlorthalidone | 55 | 18 |
| Glimepiride | Glimepiride | 55 | 16 |
| Spironolactone | Spironolactone | 55 | 17 |
| Meclizine Hcl | Meclizine Hcl | 54 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 43 |
| Ozempic | Semaglutide | 50 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Memantine Hcl | Memantine Hcl | 49 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 16 |
| Cephalexin | Cephalexin | 47 | 40 |
| Clonazepam | Clonazepam | 47 | 12 |
| Ezetimibe | Ezetimibe | 46 | 16 |
| Temazepam | Temazepam | 45 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 41 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 12 |
| Nifedipine Er | Nifedipine | 39 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Methimazole | Methimazole | 36 | 11 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 12 |
| Lovastatin | Lovastatin | 35 | 11 |
| Nabumetone | Nabumetone | 35 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 15 |
| Amoxicillin | Amoxicillin | 33 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 20 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 18 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 30 | 28 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 30 | 22 |
| Loperamide | Loperamide Hcl | 29 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Ciclopirox | Ciclopirox | 27 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 27 | 11 |
| Topiramate | Topiramate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 17 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Hydrocortisone | Hydrocortisone | 21 | 11 |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 13 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 20 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Clarithromycin | Clarithromycin | 19 | 18 |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 18 | 12 |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,002.93 · 52 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GLYCATE, KISUNLA, Kerendia, NEXLETOL, NURTEC ODT, OTEZLA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, SUBLOCADE, Stimulan, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN, ZAVZPRET, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error